Format

Send to

Choose Destination
Ann Oncol. 2014 Jul;25(7):1328-33. doi: 10.1093/annonc/mdu101. Epub 2014 Mar 5.

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Author information

1
Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, Switzerland maapro@genolier.net.
2
Comprehensive Cancer Center, University of California San Francisco, San Francisco, USA.
3
Corporate Clinical Development, Statistics and Data Management, Helsinn Healthcare, Lugano, Switzerland.
4
Department of Oncology, Dnepropetrovsk Medical Academy, Dnepropetrovsk, Ukraine.
5
Nzoz Magodent, Warsaw, Poland.
6
Oncomed SRL, Timisoara, Romania.
7
Hospital Universitario, Universidad Autonoma de Nuevo León, Monterrey, Mexico.
8
National Cancer Institute Giovanni Paolo II, Bari, Italy.
9
Department of Hematology, Oncology and Palliative Medicine, Staedt. Klinikum Neuperlach and Harlaching, München, Germany.
10
The West Clinic, Memphis.
11
Fletcher Allen Health Care, Burlington, USA.

Abstract

BACKGROUND:

Antiemetic guidelines recommend co-administration of agents that target multiple molecular pathways involved in emesis to maximize prevention and control of chemotherapy-induced nausea and vomiting (CINV). NEPA is a new oral fixed-dose combination of 300 mg netupitant, a highly selective NK1 receptor antagonist (RA) and 0.50 mg palonosetron (PALO), a pharmacologically and clinically distinct 5-HT3 RA, which targets dual antiemetic pathways.

PATIENTS AND METHODS:

This multinational, randomized, double-blind, parallel group phase III study (NCT01339260) in 1455 chemotherapy-naïve patients receiving moderately emetogenic (anthracycline-cyclophosphamide) chemotherapy evaluated the efficacy and safety of a single oral dose of NEPA versus a single oral dose (0.50 mg) of PALO. All patients also received oral dexamethasone (DEX) on day 1 only (12 mg in the NEPA arm and 20 mg in the PALO arm). The primary efficacy end point was complete response (CR: no emesis, no rescue medication) during the delayed (25-120 h) phase in cycle 1.

RESULTS:

The percentage of patients with CR during the delayed phase was significantly higher in the NEPA group compared with the PALO group (76.9% versus 69.5%; P = 0.001), as were the percentages in the overall (0-120 h) (74.3% versus 66.6%; P = 0.001) and acute (0-24 h) (88.4% versus 85.0%; P = 0.047) phases. NEPA was also superior to PALO during the delayed and overall phases for all secondary efficacy end points of no emesis, no significant nausea and complete protection (CR plus no significant nausea). NEPA was well tolerated with a similar safety profile as PALO.

CONCLUSIONS:

NEPA plus a single dose of DEX was superior to PALO plus DEX in preventing CINV following moderately emetogenic chemotherapy in acute, delayed and overall phases of observation. As a fixed-dose antiemetic drug combination, NEPA along with a single dose of DEX on day 1 offers guideline-based prophylaxis with a convenient, single-day treatment.

KEYWORDS:

CINV; NEPA; moderately emetogenic; netupitant; neurokinin-1 receptor antagonist; palonosetron

PMID:
24603643
PMCID:
PMC4071754
DOI:
10.1093/annonc/mdu101
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center